Core Viewpoint - Ctrip Group (09961.HK) is scheduled to announce its financial results on May 20, 2025, before the trading hours of the Hong Kong Stock Exchange [1] Summary by Category - **Company Announcement** - Ctrip Group will release its earnings report on May 20, 2025 [1] - The announcement will take place prior to the trading hours of the Hong Kong Stock Exchange [1]

湊湊方面表示，新品延续了湊湊"三星价格五星享受"的价值主张，通过打造独特的产品体验，在餐饮行 业激烈竞争中持续赢得消费者认可。数据显示，湊湊假期期间包间使用率为饱和状态，其中配备"奔驰 锅"的包间服务尤其受到家庭及团体客群欢迎。 记者从港股上市公司呷哺集团获悉，5月1日至5日，呷哺呷哺整体营收同比增长18.85%，北京核心商圈 门店增长超31%，新开北京定慧里门店单日营业额突破5万元。旗下品牌湊湊火锅同步发力，茶香锅 底、限定海鲜新品及包间服务拉动消费升级，旅游城市与一线近郊门店表现尤为突出，印证假日消费半 径扩大趋势。 从区域表现来看，山东、珠海、太原等旅游城市门店业绩表现突出，而北京、上海等一线城市消费呈现 新趋势——消费者更倾向前往近郊门店就餐，导致传统市区门店客流量受到一定影响，这一现象反映出 假日消费半径扩大的新特征。 具体来看，"五一"假期期间，呷哺呷哺通过产品服务及特色营销活动实现营收显著增长。数据显示，今 年5月1日至5月5日整体营收比2024年增长18.85%，其中"呷哺礼品卡"销售额达1886.5万元，显示出餐饮 消费市场活力。 在餐饮消费市场持续复苏的背景下，呷哺呷哺门店也迎来稳健扩张。 ...

今年"五一"黄金周，跨境游双向火爆趋势正在转化为实际的跨境消费活力。来自Alipay+跨境服务发布 的最新数据显示：今年"五一"，入境游客用家乡钱包游中国，广东、上海、浙江依然是热门目的地 TOP3。广东"五一"期间入境消费额全国第一，同比增长1倍多。 今年五一假期，北京、上海、广州等大型国际机场口岸的入境外国人数量持续增长，微信支付外卡数据 显示，今年五一前三天，外籍用户在境内消费笔数、金额同比都增长了近2倍。 入境游客买了啥？数据显示，盒马、名创优品排名靠前，泡泡玛特等海外年轻人也追捧的中国潮玩、海 底捞等中国餐饮连锁，也吸引了不少入境游客慕名来到"原产地"打卡。 China Travel购买力持续发酵 来自央视的调查显示，今年五一假期，北京、上海、广州等大型国际机场口岸的入境外国人数量持续增 长，北京口岸入境外国人数量同比增长80.8%，上海口岸出入境客流总量预计近60万人次……伴随入境 免签利好、离境退税和移动支付便利，不少境外游客也带着大旅行箱来华扫货，"China Travel"购买力 也在"五一"期间强劲发酵。 据悉，目前全球游客来中国消费，在支付宝侧可用"外卡内绑"和Alipay+跨境服务"外 ...

截至5月6日收盘，衍生集团（06893.HK）报0.180港元，较上个交易日上涨0.56%，当日盘中最低价触 及0.165港元，创近一年新低。 衍生集团(国际)控股有限公司(股份代号:6893)专注于开发儿科保健品、中成药、及中医相关的健康项 目。集团于1996年成立,业务遍及中国内地、香港、澳门、台湾及东南亚等地区,积极达致品牌及产品多 元化发展,照顾各个家庭的健康需要。集团以专业的管理、进取的精神、严谨的态度,凭借雄厚的实力,已 成为集研发设计、生产加工、策划推广、市场营销、物流配送为一体的中医儿童专业服务与管理企业, 并积极发展中医药文化教育及生态产业。集团旗下生产基地'衍生健康医药产业园'位于广东省云浮市云 城区,已通过'食品生产许可SC认证',具备多条可作全自动生产包装的流水线,以生产衍生品牌系列食品、 保健品等产品为主,同时专业提供优质的符合GMP要求的外品牌委托加工生产(OEM)及受委托研发设计 生产代工策划(ODM)服务,业务涵盖饮料、方便食品、糖果制品等健康食品类目。'衍生'品牌严选本草精 华,配合现代高科技,推出多元化的保健药品及食品,当中多款产品已获发中成药注册(HKC)编号,通过多项 ...

（以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 截至5月6日收盘，东京中央拍卖（01939.HK）报0.980港元，较上个交易日下跌34.67%，当日盘中最高 价触及3.180港元，创近一年新高。 本文源自金融界 资金流向方面，当日主力流入2267.276万港元，流出2186.976万港元，净流入80.30万港元。 东京中央拍卖控股有限公司(TokyoChuoAuctionHoldingsLimited)於2010年在日本东京成立,是首家於日本 公开举办中国古美术品拍卖会的拍卖公司,并屡次创下中国艺术品在日本拍卖的成交记录,备受业内及藏 家的瞩目,更为全球古董市场注入新动力。东京中央拍卖始终坚持「一期一会」的经营理念,秉承拍品来 源有据、流传有序,多年来曾至香港、台北、上海及北京举办多场预展,为藏家们呈献古代和近现代中国 书画、中国瓷器与工艺品、青铜器、茶道具、文房四宝、当代艺术、珍稀佳酿、珠宝及钟表等各类艺术 珍品拍卖。艺术之美不止於拍卖,除了每年所举办的多场拍卖会外,东京中央也积极推广艺术文化,多年来 於各地美术馆、大型展览会中举办过各类文化展览活动推动中日两国文化交流 ...

Group 1 - BlackRock's stake in Meituan-W increased from 5.77% to 6.02% as of May 1 [1]

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which opened high and is currently at 1195.47 points, reflecting a recent decline of 2.95% over the past month but an increase of 13.55% over the last three months and 13.14% year-to-date [1][2] - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotech services from the mainland and Hong Kong markets, serving as a benchmark for the overall performance of biotech-themed securities [1][2] - The top ten weighted companies in the index include: Hengrui Medicine (13.31%), BeiGene (10.94%), WuXi AppTec (8.63%), Mindray Medical (7.77%), WuXi Biologics (5.11%), Innovent Biologics (4.73%), CanSino Biologics (3.38%), CSPC Pharmaceutical Group (2.73%), China National Pharmaceutical Group (2.41%), and Shanghai RAAS Blood Products (1.82%) [1][2] Group 2 - The index's holdings are distributed across different market exchanges, with the Hong Kong Stock Exchange accounting for 41.35%, Shanghai Stock Exchange for 36.05%, and Shenzhen Stock Exchange for 22.61% [1][2] - In terms of industry composition, biopharmaceuticals represent 42.86%, chemical drugs 25.82%, pharmaceutical and biotech services 21.73%, and medical devices 9.59% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year, ensuring that the weight factors are updated accordingly [2]

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Comprehensive Index reported a value of 1467.39 points, showing a monthly increase of 0.37%, a three-month increase of 10.32%, and a year-to-date increase of 11.90% [1] - The index is designed to reflect the overall performance of different industry securities within the Hong Kong Stock Connect, categorized according to the China Securities Industry Classification Standard [1] - The top ten weighted stocks in the index include JD Health (15.7%), Alibaba Health (15.39%), Sinopharm (11.5%), Weigao Group (7.35%), MicroPort Medical (4.9%), Ping An Good Doctor (4.63%), Shanghai Pharmaceuticals (3.7%), MicroPort Scientific-B (3.6%), Xianjian Technology (3.16%), and Jinxin Fertility (3.03%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.51%, medical services for 23.49%, medical consumables for 23.03%, medical devices for 3.98%, and in vitro diagnostics for 0.98% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments in case of special events affecting the index sample [2]

Group 1 - The core viewpoint of the article highlights the performance of the China Securities Hong Kong Stock Connect Repurchase Index, which has shown a decline of 4.81% over the past month, an increase of 8.84% over the past three months, and a year-to-date rise of 8.00% [1] - The index is composed of 50 stocks with high repurchase ratios selected from the Hong Kong Stock Connect, reflecting the overall performance of these high repurchase companies [1] - The index was established on December 28, 2018, with a base value of 1000.0 points [1] Group 2 - The top ten holdings of the index include HSBC Holdings (10.68%), AIA Group (9.98%), Tencent Holdings (9.97%), Meituan-W (8.04%), Kuaishou-W (7.79%), Dongyue Group (6.48%), Swire Properties A (5.4%), Hang Seng Bank (5.38%), CSPC Pharmaceutical Group (4.36%), and China COSCO Holdings (3.71%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry distribution, the index sample shows that finance accounts for 26.04%, communication services for 18.37%, consumer discretionary for 15.47%, healthcare for 11.62%, real estate for 8.92%, materials for 6.67%, industrials for 6.28%, energy for 3.36%, information technology for 2.05%, and consumer staples for 1.21% [2] - The index samples are adjusted quarterly, with adjustments occurring on the next trading day following the second Friday of March, June, September, and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample stock is delisted or undergoes mergers, acquisitions, or spin-offs [2]

金融界5月6日消息，上证指数高开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1276.34点。 从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通生物科技主题指数持仓样本的行业来看，生物药品占比52.26%、化学药占比25.22%、制 药与生物科技服务占比19.39%、医疗器械占比3.13%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。当港股通范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 数据统计显示，中证港股通生物科技主题指数近一个月上涨0.05%，近三个月上涨31.09%，年至今上涨 32.29%。 据了解，中证港股通生物科技主题指数从港股通范 ...